Center for Medicare Advocacy

Advancing Access to Medicare and Healthcare

antipsychotics

Antipsychotic Drugs and Nursing Home Residents: What Do the Different Numbers Mean?

Last week’s Alert discussed the Centers for Medicare & Medicaid Services’ (CMS’s) National Partnership to Improve Dementia Care and the Government Accountability Office’s (GAO) recent report on antipsychotic … [Read more...] about Antipsychotic Drugs and Nursing Home Residents: What Do the Different Numbers Mean?

Has CMS’s Partnership with the Nursing Home Industry Really Reduced the Inappropriate Use of Antipsychotic Drugs by Nursing Home Residents as Much as CMS Claims? No.

In September 2014, the Centers for Medicare & Medicaid Services (CMS)[1] reported that the National Partnership to Improve Dementia Care had reduced the use of antipsychotic drugs with nursing home residents by 15.1%, “exceeding” the … [Read more...] about Has CMS’s Partnership with the Nursing Home Industry Really Reduced the Inappropriate Use of Antipsychotic Drugs by Nursing Home Residents as Much as CMS Claims? No.

CMA Report: Inappropriate Use of Antipsychotic Drugs in Nursing Homes, Part Three – Recommendations to Improve the Citing of Deficiencies

As required by the 1987 federal Nursing Home Reform Law,[1] CMS has developed, tested, and periodically revised a survey protocol that state surveyors, who are generally employed by the state health departments, must use to determine nursing … [Read more...] about CMA Report: Inappropriate Use of Antipsychotic Drugs in Nursing Homes, Part Three – Recommendations to Improve the Citing of Deficiencies

CMA Report on Inappropriate Use of Antipsychotic Drugs in Nursing Homes – Part Two: What the Surveyors Say

The Center for Medicare Advocacy (the Center) has reported on the misuse of antipsychotic drugs by nursing homes for many years, discussing Congressional hearings and federal reports and the high personal and financial cost of the misuse of the … [Read more...] about CMA Report on Inappropriate Use of Antipsychotic Drugs in Nursing Homes – Part Two: What the Surveyors Say

CMA Report: Examining Inappropriate Use of Antipsychotic Drugs in Nursing Facilities

The misuse of antipsychotic drugs by nursing homes has been the subject of Congressional hearings and Government reports for many decades.[1]  More than 300,000 nursing home residents take antipsychotic drugs and, as the Inspector General found, … [Read more...] about CMA Report: Examining Inappropriate Use of Antipsychotic Drugs in Nursing Facilities

Misuse of Antipsychotic Drugs in Nursing Homes: Are We Making Any Progress?

The recent settlement of criminal and civil charges against Johnson & Johnson for off-label marketing of Risperdal for nursing home residents once again brings the issue of antipsychotic drugs and nursing homes to public attention.  A group … [Read more...] about Misuse of Antipsychotic Drugs in Nursing Homes: Are We Making Any Progress?

$2.2 Billion Johnson & Johnson Settlement Sends New Warning: Antipsychotic Drugs Should Not Be Used to Treat Dementia

November 14, 2013 For Immediate ReleaseStatement of California Advocates for Nursing Home Reform, Center for Medicare Advocacy, Legal Aid Justice Center, Long Term Care Community Coalition, The National Consumer Voice for Quality Long-Term … [Read more...] about $2.2 Billion Johnson & Johnson Settlement Sends New Warning: Antipsychotic Drugs Should Not Be Used to Treat Dementia

Examining Inappropriate Use of Antipsychotic Drugs, Part One: How Seven States Cite Antipsychotic Drug Deficiencies

The misuse of antipsychotic drug is a pervasive problem in American nursing facilities.  Misuse causes physical and psychological harm and death to residents and costs many hundreds of millions of dollars annually,[1] both for the drugs … [Read more...] about Examining Inappropriate Use of Antipsychotic Drugs, Part One: How Seven States Cite Antipsychotic Drug Deficiencies